RecruitingMajor Depressive Disorder
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Eligible age
18+ yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Sponsor: Neurocrine Biosciences
Where it's recruiting
California
Chino · Los Angeles · Stanford
Colorado
Aurora
Connecticut
Cromwell · Farmington
Florida
Maitland · Miami · Tampa
Maryland
Gaithersburg
New York
Cedarhurst · New York
North Carolina
Charlotte
Pennsylvania
Philadelphia
Source: ClinicalTrials.gov · NCT06963021 · last updated 2026-06-23